Publication | Closed Access
In Vitro Assay of Cellular Immunity to Tumor-Specific Antigen(s) of Virus-Induced Tumors by Macrophage Migration Inhibition
35
Citations
0
References
1973
Year
Laboratory ImmunologyImmunologyImmunoeditingImmunodominancePathologyImmunotherapeuticsTumor-specific AntigenImmune SystemImmunotherapyTumor ImmunologyTumor ImmunityCell TransplantationRadiation OncologyAllergyMacrophage Migration InhibitionImmunoengineeringTherapeutic VaccineVirologyImmune SurveillanceAutoimmunityT Cell ImmunityVirus-induced TumorsTransplantation RejectionTumor MicroenvironmentMacrophage MigrationOncogenic Dna VirusesCancer ImmunosurveillanceImmunomodulationImmunosuppressionMedicineViral OncologyViral Immunity
Abstract It has been well established that transformation of cells by oncogenic DNA viruses leads to the expression of virus-specific antigens, among which are the tumor-specific transplantation antigens (TSTA)4 (1–6). While the immune response to these antigens can be detected in vivo by transplantation rejection (1, 2), the procedure is time-consuming, requires a great deal of material and large numbers of animals and is difficult to quantitate. Inhibition of macrophage migration has been a useful tool for in vitro studies of delayed hypersensitivity (7). It has been used to study this phenomenon in guinea pigs, rats, mice, hamsters and man (8, 9). Earlier studies with this technique detected reactivity against tuberculin, other microbial antigens, pure protein antigens, viral antigens, and normal tissue alloantigens (8). The test has also been used to measure cellular immunity in mice to antigens associated with Moloney sarcoma virusinduced tumors (10) and spontaneous mammary carcinoma (11), as well as to detect tumor-specific antigens of tumors induced by chemical carcinogens (12–15).